| BSE: 500257 | Sector: Health care |
| NSE: LUPIN | ISIN Code: INE326A01037 |
| BSE 00:00 | 24 Sep | 859.05 |
-30.70 (-3.45%) |
OPEN
899.95 |
HIGH
920.00 |
LOW
851.45 |
| NSE 00:00 | 24 Sep | 860.75 |
-29.50 (-3.31%) |
OPEN
896.00 |
HIGH
903.00 |
LOW
851.60 |
| OPEN | 899.95 |
| PREVIOUS CLOSE | 889.75 |
| VOLUME | 289456 |
| 52-Week high | 1090.00 |
| 52-Week low | 723.55 |
| P/E | 27.35 |
| Mkt Cap.(Rs cr) | 38,842 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
12.30 pm | 22 Sep 2018 | Business Standard
The CHMP opinion for the drug to be sold under the named Fulphila will now be considered by the European Commission and the decision on approval is ex...
9.43 pm | 21 Sep 2018 | Business Standard
The National Company Law Tribunal (NCLT), Chennai Bench has approved the resolution plan submitted by US-based investor Ingen Capital Group LLC for Ch...
7.48 pm | 21 Sep 2018 | Press Trust of India
The initial public offer (IPO) is expected to fetch Rs 4.5 billion
1.45 pm | 21 Sep 2018 | Press Trust of India
ILUMYA is one of the key specialty products of Sun Pharma and it was approved by the US health regulator USFDA in March 2018 while the European Commis...
4.17 pm | 20 Sep 2018 | Business Standard
With the Max Healthcare deal, Radiant would have access to 14 hospitals led by Max
8.52 am | 19 Sep 2018 | Business Standard
At the 14th AGM, RCom Chairman Anil Ambani announced that the company will exit telecom business completely, owing to intense slugfest in the sector.
11.36 pm | 17 Sep 2018 | Business Standard
SC did not grant any relief to the other medicines in the list of 328 FDC drugs, which were banned by the Health Ministry by its September 7 notificat...
6.06 pm | 17 Sep 2018 | Press Trust of India
The approved product is a generic version of Novo Nordisk Inc's VAGIFEM
12.41 am | 17 Sep 2018 | Business Standard
Of over 140 products in pipeline, at least 10 are para IV filings
1.54 am | 15 Sep 2018 | Business Standard
The Ranbaxy-Daiichi issue - all emerged within one year. I said I had taken a one-way ticket to Beas and was not interested, but, then, because I had ...
12.29 am | 15 Sep 2018 | Business Standard
The top seven brands have together grown at 21 per cent annually and now account for 46 per cent of Sanofi's sales
10.37 am | 14 Sep 2018 | Business Standard
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-an...
10.37 am | 14 Sep 2018 | Business Standard
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-an...
10.37 am | 14 Sep 2018 | Business Standard
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-an...
10.37 am | 14 Sep 2018 | Business Standard
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-an...
10.37 am | 14 Sep 2018 | Business Standard
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-an...
1.50 am | 14 Sep 2018 | Business Standard
Their mother has acted as the peacemaker, however, Shivinder might take legal route again if the conflict is not resolved through mediation
9.23 pm | 13 Sep 2018 | Business Standard
This addition of new beds would add to the already existing 10,000 beds it has across 70 hospitals
5.19 pm | 12 Sep 2018 | Press Trust of India
As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around $117.4 million in the US
2.33 pm | 12 Sep 2018 | Business Standard
The stock has moved higher by 4% to Rs 655, bouncing back 6% from its early morning low of Rs 620 on the BSE on Wednesday.
